December 6, 2018 / 10:26 PM / in 8 days

BRIEF-FDA approves Genentech’S tecentriq in combination with avastin and chemotherapy

Dec 6 (Reuters) - Roche Holding AG:

* FDA APPROVES GENENTECH’S TECENTRIQ IN COMBINATION WITH AVASTIN AND CHEMOTHERAPY FOR THE INITIAL TREATMENT OF PEOPLE WITH A SPECIFIC TYPE OF METASTATIC LUNG CANCER

* GENENTECH SAYS APPROVAL IS BASED ON RESULTS FROM PHASE III IMPOWER150 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below